Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Posch, C, Cholewa, BD, Vujic, I, Sanlorenzo, M, Ma, J, Kim, ST, Kleffel, S, Schatton, T, Rappersberger, K, Gutteridge, R, Ahmad, N, Ortiz/Urda, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567913/
https://www.ncbi.nlm.nih.gov/pubmed/26016894
http://dx.doi.org/10.1038/jid.2015.198

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4567913/
https://www.ncbi.nlm.nih.gov/pubmed/26016894
http://dx.doi.org/10.1038/jid.2015.198

Ejemplares similares